Is It Too Late to Buy Novavax Stock?
Novavax (NASDAQ: NVAX) stock is suddenly a buy again this year, with its stock price more than tripling since the start of 2024. Some positive developments in recent months, including a deal with Sanofi (NASDAQ: SNY), gave the market some renewed hope in this beaten-down COVID-19-related stock. It was all that long ago that there were real concerns about the company going out of business.
With Novavax already accumulating such impressive gains this year (it's up 234%), is it too late to invest in the healthcare stock, or is there still a chance to get in on what could be the start of a much bigger rally?
Novavax stock hit a new 52-week high of $23.86 last week, and while it has come down from there in recent days, the stock's price remains at levels it hasn't seen since late 2022.
Source Fool.com
Novavax Inc. Aktie
Leichtes Buy-Übergewicht bei Novavax Inc. mit 8 Buy- gegenüber 3 Sell-Einschätzungen.
Das Kursziel von 11 € für Novavax Inc. weist auf eine Steigerung von über 20% gegenüber dem aktuellen Kurs von 7.37 € hin.
